5mon
Medpage Today on MSNCytokine Release Syndrome and Neurotoxicity After CAR T-Cell TherapyThe most frequent of these immune-mediated toxicities are cytokine release syndrome (CRS) and immune effector ... Jain ...
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
Since 1941, when Gregg first described the triad of deafness, cataracts and cardiac disease as the classical clinical manifestations of congenital rubella syndrome (CRS), strong efforts have been ...
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
Hosted on MSN12mon
New research results explore the safety of short-term cultivated CAR T cells in cancer immunotherapyMore information: Arezoo Jamali et al, Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models, EMBO Molecular Medicine (2024). DOI: 10.1038/s44321-024 ...
TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results